Brian Park, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Obesity

Tesomet Receives Orphan Drug Status for Hypothalamic Obesity

Brian Park, PharmD

July 29, 2021

Tesomet is an investigational fixed-dose combination therapy of tesofensine, a triple monoamine reuptake inhibitor, and metoprolol, a beta-1 selective blocker.

Pediatric Endocrinology

Bydureon BCise Approved for Adolescents With Type 2 Diabetes

Brian Park, PharmD

July 27, 2021

The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes.

Diabetes

FDA Approves Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy

Brian Park, PharmD

July 26, 2021

Nevro’s SCS system for painful diabetic neuropathy will be available under the brand name HFX™ for PDN.

Diabetes

Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease

Brian Park, PharmD

July 14, 2021

The approval was based on data from the phase 3 FIDELIO-DKD trial.

General Endocrinology

Pfizer-BioNTech: Update on COVID-19 Booster Shot; Reformulated Vaccine in the Works

Brian Park, PharmD

July 13, 2021

An updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant is also in the works.

Type 1 Diabetes

FDA Rejects Teplizumab BLA for Type 1 Diabetes

Brian Park, PharmD

July 12, 2021

Teplizumab is an investigational anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.

Type 1 Diabetes

Zegalogue Now Available for Severe Hypoglycemia

Brian Park, PharmD

June 29, 2021

The product should be stored in a refrigerator but can be kept at room temperature for up to 12 months.

Androgen and Reproductive Disorders

Novel Oral Contraceptive Nextstellis Now Available

Brian Park, PharmD

June 24, 2021

The approval was based on data from two phase 3 studies that evaluated the safety, acceptability, efficacy, and cycle control of Nextstellis in 3725 women aged 16 to 50.

Lipids and Cholesterol

FDA: More Data Needed to Support Arimoclomol in Niemann-Pick Disease Type C

Brian Park, PharmD

June 23, 2021

Arimoclomol is an investigational oral drug candidate that is designed to amplify and sustain the cellular production of heat shock proteins.

Androgen and Reproductive Disorders

Myfembree Now Available for Heavy Menstrual Bleeding With Uterine Fibroids

Brian Park, PharmD

June 23, 2021

Myfembree consists of relugolix, a gonadotropin-releasing hormone receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin.

Next post in Androgen and Reproductive Disorders